Upstream Bio (UPB) Projected to Post Quarterly Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) is expected to post its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect Upstream Bio to post earnings of ($0.73) per share and revenue of $0.5220 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 19, 2026 at 12:30 PM ET.

Upstream Bio Stock Performance

Shares of UPB opened at $7.66 on Monday. The company has a market cap of $413.95 million, a price-to-earnings ratio of -4.07 and a beta of 3.00. The stock has a fifty day moving average price of $21.92 and a two-hundred day moving average price of $22.37. Upstream Bio has a 52-week low of $5.14 and a 52-week high of $33.68.

Analyst Upgrades and Downgrades

UPB has been the topic of several research analyst reports. Evercore initiated coverage on Upstream Bio in a report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 target price on the stock. Mizuho raised Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st. Finally, Lifesci Capital initiated coverage on shares of Upstream Bio in a report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Upstream Bio has an average rating of “Moderate Buy” and an average target price of $45.25.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Upstream Bio by 12.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock valued at $45,944,000 after buying an additional 271,718 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Upstream Bio during the fourth quarter valued at $41,423,000. State Street Corp boosted its holdings in Upstream Bio by 18.4% in the fourth quarter. State Street Corp now owns 1,319,226 shares of the company’s stock valued at $35,817,000 after acquiring an additional 204,645 shares during the last quarter. Marshall Wace LLP boosted its holdings in Upstream Bio by 198.8% in the third quarter. Marshall Wace LLP now owns 867,999 shares of the company’s stock valued at $16,327,000 after acquiring an additional 577,473 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Upstream Bio by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 851,908 shares of the company’s stock worth $23,134,000 after purchasing an additional 34,799 shares during the period.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.